As a class of drugs specifically targeted to tumors, TROP2-targeted therapeutics are widely regarded as poised to transform the future of solid tumor therapy, such as gastric cancer, pancreatic cancer, breast cancer, prostate cancer (58–61). The gene discussed is TACSTD2; the disease is familial pancreatic carcinoma.